La Jolla, CA, United States of America

Elai Davicioni

This inventor holds 15 USPTO granted patents and 21 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Cancer Diagnostics. Top assignees: Decipher Biosciences, Inc., Genomedx Biosciences Inc., Mayo Foundation for Medical Education and Research. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elai Davicioni. Retrieved from https://idiyas.com/inventor/elai-davicioni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 2.6

ph-index = 7

Forward Citations = 162(Granted Patents)


Location History:

  • Vancouver, CA (2015 - 2019)
  • La Jolla, CA (US) (2018 - 2024)

Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Gene Expression
Prostate Cancer
Radiation Therapy
Biomarkers
Machine Learning
Genomic Signatures
Tumor Aggressiveness
Thyroid Nodule
Cancer Prognosis
Clinical Disease States
Non-Coding Transcripts
Bladder Cancer
15 patents (USPTO):Explore Patents

Title: **Elai Davicioni: Innovator in Machine Learning and Cancer Diagnostics**

Introduction

Elai Davicioni is a prominent inventor based in La Jolla, California, known for his significant contributions to the fields of machine learning and cancer diagnostics. With an impressive portfolio of 14 patents, Davicioni has made remarkable advancements aimed at enhancing predictive analytics and treatment methodologies in oncology.

Latest Patents

Some of Elai Davicioni's latest patents include:

1. **Systems and methods for preprocessing target data and generating predictions using a machine learning model**: This innovative patent describes a methodology where a machine learning model generates a likelihood score related to a condition. By utilizing pre-computed vectors derived from a training dataset, the model processes target data to generate accurate predictions. This approach allows for normalized target data using the pre-computed vectors, enhancing the model's predictive capabilities.

2. **Subtyping prostate cancer to predict response to hormone therapy**: This invention involves various methods, systems, and kits for the diagnosis and prognosis of prostate cancer. It introduces biomarkers that define distinct subgroups of the disease, including clinically useful classifiers for differentiating prostate cancer subtypes. The patent underlines bioinformatic methods that improve cancer treatment based on molecular subtyping, providing vital tools for treating patients more effectively.

Career Highlights

Elai Davicioni has worked with notable companies in the biotech sector, including Decipher Biosciences, Inc. and Genomedx Biosciences Inc. His expertise and innovative mindset have propelled advancements in cancer diagnostics and machine learning applications, solidifying his reputation as a leader in these domains.

Collaborations

During his career, Elai has collaborated with esteemed colleagues such as Nicholas Erho and Sam Michael Wiseman. Through these partnerships, he has been able to drive forward groundbreaking research and development efforts, contributing significantly to improving clinical outcomes in cancer treatment.

Conclusion

Elai Davicioni exemplifies the spirit of innovation within the field of medical technology. With his extensive patent portfolio and collaborations, he is paving the way for enhanced predictive analytics in cancer therapy and diagnostics. His work continues to influence advancements in machine learning and prostate cancer treatment, making a lasting impact in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…